Quest for the right Drug

|
עמוד הבית / מיוויו / מידע מעלון לרופא

מיוויו MYOVIEW (TETROFOSMIN)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-ורידי : I.V

צורת מינון:

אבקה מיובשת בהקפאה להכנת תמיסה להזרקה : LYOPHILIZED POWDER FOR SOLUTION FOR INJECTION

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1     Pharmacodynamic properties

Pharmacotherapeutic group: diagnostic radiopharmaceuticals, cardiovascular system, technetium (99mTc) tetrofosmin, ATC Code: V09GA02.

Pharmacological effects are not expected following intravenous administration of reconstituted Myoview at the recommended dosage. Studies in animals have shown that myocardial uptake of tetrofosmin (99mTc) is linearly related to coronary blood flow, confirming the effectiveness of the complex as a myocardial perfusion imaging agent.
Based upon clinical experience with ECG-gated myocardial perfusion scintigraphy, this method can be used to monitor for changes (or stability) in left ventricular function over time.
Reliability of such serial assessment is expected to be similar to that of other commonly used measurement techniques (e.g. ECG-gated blood-pool scintigraphy).

Limited data in animals show uptake of tetrofosmin (99mTc) into breast tumour cells.

Pharmacokinetic Properties

5.2     Pharmacokinetic properties
Organ uptake
Myocardial uptake in the myocardium is rapid, reaching a maximum of about 1.2% of injected dose with sufficient retention to allow imaging of the myocardium by planar or SPECT techniques from 15 minutes up to 4 hours post-administration.

Elimination
Tetrofosmin (99mTc) is rapidly cleared from the blood after intravenous injection; less than 5% of the administered activity remains in whole blood at 10 minutes post-injection. Background tissue clearance is rapid from lung and liver and activity is reduced in these organs following exercise, with enhanced sequestration in skeletal muscle. Approximately 66% of the injected activity is excreted within 48 hours post-injection, with approximately 40% excreted in the urine and 26% in the faeces.

Half-life
Sodium Pertechnetate (99mTc) Injection Ph.Eur. is produced by a [99Mo/99mTc] generator.
Technetium (99mTc) disintegrates with the emission of gamma radiation (energy 141 keV) and a half-life of 6.02 hours.

Renal/hepatic impairment
The pharmacokinetics in patients with renal or hepatic impairment has not been characterized.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

רישום

100 19 28394 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

17.10.21 - עלון לרופא 11.05.23 - עלון לרופא 21.09.23 - עלון לרופא

עלון מידע לצרכן

11.01.21 - החמרה לעלון 17.10.21 - החמרה לעלון 11.05.23 - החמרה לעלון 21.09.23 - החמרה לעלון

לתרופה במאגר משרד הבריאות

מיוויו

קישורים נוספים

RxList WebMD Drugs.com